Director Feinberg gets 3,251 RSUs at Edwards Lifesciences (EW)

Rhea-AI Filing Summary

Feinberg David T reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences Corp director David T. Feinberg received an equity grant of 3,251 shares of common stock in the form of restricted stock units. The award was granted at a price of $0.00 per share under the company’s 2020 Nonemployee Directors Stock Incentive Program.

The units are scheduled to become 100% vested after the earlier of one year from the May 8, 2026 grant date or the company’s next annual meeting of stockholders. Following this grant, Feinberg holds a total of 9,087 shares of common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Feinberg David T

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,251	$0.00	--

Holdings After Transaction: Common Stock — 9,087 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 3,251 shares Grant price: $0.00 per share Total shares after grant: 9,087 shares +1 more

4 metrics

RSUs granted 3,251 shares Restricted stock units granted on May 8, 2026

Grant price $0.00 per share Equity award to director David T. Feinberg

Total shares after grant 9,087 shares Director’s direct holdings following transaction

Vesting condition 100% after earlier of 1 year or next annual meeting Vesting terms for 3,251 restricted stock units

Key Terms

restricted stock units, 2020 Nonemployee Directors Stock Incentive Program, vested

3 terms

restricted stock units financial

"These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Nonemployee Directors Stock Incentive Program financial

"These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program."

vested financial

"They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feinberg David T

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/08/2026		A		3,251(1)	A	$0.0000	9,087	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Edwards Lifesciences (EW) report for David T. Feinberg?

Edwards Lifesciences reported that director David T. Feinberg received 3,251 restricted stock units of common stock. The grant was awarded at $0.00 per share as part of director compensation and increases his direct holdings to 9,087 shares after the transaction.

How many shares did David T. Feinberg acquire in this Edwards Lifesciences (EW) Form 4 filing?

David T. Feinberg acquired 3,251 shares in the form of restricted stock units. These units were granted as compensation and added to his existing position, bringing his total direct holdings in Edwards Lifesciences common stock to 9,087 shares following the grant.

What is the vesting schedule for David T. Feinberg’s 3,251 restricted stock units at Edwards Lifesciences (EW)?

The 3,251 restricted stock units granted to David T. Feinberg are scheduled to become 100% vested after the earlier of one year from the May 8, 2026 grant date or Edwards Lifesciences’ next annual meeting of stockholders, providing a clear, time-based vesting condition.

Under which plan were David T. Feinberg’s restricted stock units granted at Edwards Lifesciences (EW)?

The restricted stock units granted to David T. Feinberg were issued under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. This plan provides stock-based compensation specifically designed for nonemployee directors serving on the company’s board.

What is David T. Feinberg’s total direct ownership in Edwards Lifesciences (EW) after this Form 4 transaction?

After receiving the 3,251 restricted stock units, David T. Feinberg directly owns 9,087 shares of Edwards Lifesciences common stock. This figure reflects his total direct holdings reported in the Form 4 filing following the May 8, 2026 equity grant.